Tectonic Advisors LLC Has $847,000 Stock Holdings in Stryker Co. (NYSE:SYK)

Tectonic Advisors LLC grew its position in Stryker Co. (NYSE:SYK) by 2.7% in the 4th quarter, Holdings Channel reports. The institutional investor owned 2,354 shares of the medical technology company’s stock after purchasing an additional 63 shares during the period. Tectonic Advisors LLC’s holdings in Stryker were worth $847,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Czech National Bank raised its holdings in Stryker by 8.1% during the 3rd quarter. Czech National Bank now owns 69,843 shares of the medical technology company’s stock worth $25,231,000 after purchasing an additional 5,235 shares during the last quarter. Dynamic Advisor Solutions LLC grew its position in shares of Stryker by 2.3% during the 3rd quarter. Dynamic Advisor Solutions LLC now owns 2,990 shares of the medical technology company’s stock worth $1,080,000 after buying an additional 67 shares during the period. Atomi Financial Group Inc. raised its stake in shares of Stryker by 2.3% during the third quarter. Atomi Financial Group Inc. now owns 2,091 shares of the medical technology company’s stock worth $755,000 after buying an additional 47 shares during the last quarter. Sugarloaf Wealth Management LLC lifted its holdings in Stryker by 32.7% in the third quarter. Sugarloaf Wealth Management LLC now owns 446 shares of the medical technology company’s stock valued at $161,000 after buying an additional 110 shares during the period. Finally, Reliant Investment Management LLC boosted its stake in Stryker by 0.9% in the third quarter. Reliant Investment Management LLC now owns 15,200 shares of the medical technology company’s stock valued at $5,491,000 after acquiring an additional 138 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 1.7 %

Stryker stock opened at $399.01 on Thursday. The firm has a 50-day moving average of $376.87 and a 200-day moving average of $364.00. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The company has a market cap of $152.11 billion, a price-to-earnings ratio of 51.42, a P/E/G ratio of 2.78 and a beta of 0.96.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the firm earned $3.46 EPS. On average, equities analysts expect that Stryker Co. will post 13.5 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.84%. Stryker’s dividend payout ratio is 43.30%.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Stifel Nicolaus upped their target price on shares of Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Robert W. Baird increased their target price on Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. UBS Group raised their target price on Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Canaccord Genuity Group upped their price target on Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Finally, Truist Financial lifted their price objective on shares of Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research note on Thursday, January 30th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $419.37.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 5.50% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.